Sangamo Therapeutics (NASDAQ:SGMO) Trading Up 25.5% - Still a Buy?

Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) rose 25.5% on Monday . The stock traded as high as $2.59 and last traded at $2.57. Approximately 4,776,585 shares changed hands during trading, a decline of 29% from the average daily volume of 6,772,263 shares. The stock had previously closed at $2.05.

Analyst Upgrades and Downgrades

SGMO has been the topic of a number of analyst reports. StockNews.com lowered shares of Sangamo Therapeutics from a "buy" rating to a "hold" rating in a research report on Friday, December 6th. HC Wainwright reissued a "buy" rating and set a $10.00 price objective on shares of Sangamo Therapeutics in a report on Tuesday, December 10th. Barclays lifted their price target on shares of Sangamo Therapeutics from $3.00 to $9.00 and gave the company an "overweight" rating in a report on Thursday, November 14th. Finally, Truist Financial raised shares of Sangamo Therapeutics from a "hold" rating to a "buy" rating and set a $7.00 target price for the company in a research note on Friday. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat.com, Sangamo Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $7.00.

Sangamo Therapeutics Price Performance

The stock has a market capitalization of $550.84 million, a P/E ratio of -3.52 and a beta of 1.15. The stock's 50-day simple moving average is $1.84 and its 200 day simple moving average is $1.09.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported $0.04 earnings per share for the quarter, topping the consensus estimate of ($0.03) by $0.07. The company had revenue of $49.41 million for the quarter, compared to analysts' expectations of $26.55 million. Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. During the same period in the previous year, the business posted ($0.34) earnings per share. As a group, analysts expect that Sangamo Therapeutics, Inc. will post -0.46 earnings per share for the current fiscal year.

Institutional Trading of Sangamo Therapeutics

Several institutional investors have recently made changes to their positions in the business. Meritage Portfolio Management lifted its stake in shares of Sangamo Therapeutics by 8.6% during the 3rd quarter. Meritage Portfolio Management now owns 85,000 shares of the biopharmaceutical company's stock worth $74,000 after acquiring an additional 6,740 shares during the last quarter. Wealth Enhancement Advisory Services LLC increased its holdings in Sangamo Therapeutics by 55.4% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 108,945 shares of the biopharmaceutical company's stock worth $94,000 after purchasing an additional 38,850 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in Sangamo Therapeutics by 5.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,103,326 shares of the biopharmaceutical company's stock worth $956,000 after purchasing an additional 57,125 shares during the period. XTX Topco Ltd increased its holdings in shares of Sangamo Therapeutics by 167.8% in the 3rd quarter. XTX Topco Ltd now owns 103,716 shares of the biopharmaceutical company's stock valued at $90,000 after acquiring an additional 64,981 shares during the period. Finally, Golden State Equity Partners grew its stake in Sangamo Therapeutics by 35.2% during the 3rd quarter. Golden State Equity Partners now owns 266,484 shares of the biopharmaceutical company's stock worth $231,000 after buying an additional 69,368 shares during the last quarter. Hedge funds and other institutional investors own 56.93% of the company's stock.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.